

# ***Cardio-Renal Syndrome and Diuretic Resistance: Mechanism and Clinical Implications***

presented by

***Jeffrey M Testani, MD***

**11/14/2023 12:00:00 PM**

**Learning Objectives:** *As a result of participating in this Live Activity, participants should be able to:*

- 1 discuss current guidelines in order to provide optimal care to admitted medical and surgical cardiac patients*
- 2 apply current guidelines in order to provide optimal care to admitted medical and surgical cardiac patients*
- 3 review current cases in order to apply the latest evidence based recommendations for treatment*
- 4 identify opportunities for additional education, multispecialty collaboration, and quality improvement in the Heart and Vascular Institute*

**Accreditation Statement:** In support of improving patient care, Hartford HealthCare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

**Credit Designation Statement:** Hartford Healthcare designates this Live Activity for 1.00 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with their participation. This activity is approved for 1.00 ANCC contact hour(s).

**Financial Disclosures:**

- Jeffrey M Testani, MD : Consulting Fee-Boehringer Ingelheim, Bristol Myers Squibb, Cardionomic, MagentaMed, Reprieve inc., FIRE1, Sequana Medical, Merck, Windtree Therapeutics, Precardia, Regeneron, BD, Edwards life sciences, and Lilly. |Grant or research support-Boehringer Ingelheim, Bristol Myers Squibb, Reprieve inc., Sequana Medical, Abbott, Merck|Royalties or Patent Beneficiary-MT has a patent Treatment of diuretic resistance issued to Yale and Corvidia Therapeutics Inc, a patent Methods for measuring reninase issued to Yale, and a patent Treatment of diuretic resistance pending with Reprieve inc. |Stocks or stock options, excluding diversified mutual funds-Reprieve inc. Sequana Medical - 10/24/2023



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION